HIGHLIGHTS  LVAD implantation improves early renal function in the majority of patients  Subsequent to improvement, renal function regresses to pre-operative values  Early renal function improvement is associated with worse pre-operative conditions  Early renal function is associated with increased 2-year survival rates  Sustained renal function improvement is present in a small percentage of patients Methods: A retrospective multi-center cohort study, including all patients undergoing LVAD (HeartMate II (n=330), HeartMate 3 (n=22) and HeartWare (n=48) implantation. In total, 227 (56.8%) patients were implanted as bridge-to-transplantation, 154 (38.5%) as destination therapy and 19 (4.7%) as bridge-to-decision. Serum creatinine measurements were collected over a 2-
year follow-up period. Patients were stratified based on CKD stage.
Results:
Overall, 400 patients (mean age 53±14 years, 75% male) were included: 186 (46.5%) patients had CKD stage 1 or 2, 93 (23.3%) CKD stage 3a, 82 (20.5%) CKD stage 3b, and 39 (9.8%) patients had CKD stage 4 or 5 prior to LVAD implantation. During a median follow-up of 179 days [IQR 28-627], 32629 creatinine measurements were available. Improvement of kidney function was noticed in every preoperative CKD stage group. Following this improvement, eGFR regressed to baseline values for all CKD stages. Patients showing early renal function improvement were younger and in worse pre-operative condition. Moreover, survival rates were higher in patients showing early improvement (69% vs 56%, log-rank p=0.013).
Conclusions:
Renal function following LVAD implantation is characterized by improvement, steady state and subsequent deterioration. Patients who showed early renal function improvement were in worse pre-operative condition, however, had higher survival rates at 2-years of followup. Following LVAD implantation, several studies have reported that mean renal function improves within the first month.(2,7) However, this mean increase seems to be largely of transient nature, as mean renal function deteriorates subsequent to the improvement. This was largely confirmed by Brisco et al, when they analyzed the interagency registry for mechanically assisted circulatory support (INTERMACS).(2) They noticed a marked improvement of mean renal function following LVAD implantation, and a subsequent deterioration of renal function. The mechanisms as to why and how some patients renal function improves and why most patients subsequently deteriorate is yet to be elucidated. Subsequently, it was hypothesized that perhaps intrinsic renal injury, continuous flow physiology, hemolysis and neuro-hormonal activity could be the reason for this deterioration. Importantly, however, their utilized methodology to depict renal function is limited by the use of means at set points in time and their restricted follow-up period. This methodology favors the renal function of survivors and therefore may not accurately depict the evolution of renal function. There is a great demand for longitudinal assessment of renal function following LVAD implantation. Therefore, the aim of this study was to investigate the impact of prolonged LVAD support on changes in renal function and to identify patient related factors associated with renal function improvement following LVAD implantation.
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Methods
Study Design
We retrospectively reviewed all patients who received a LVAD between October 2004 and April 
Results
Baseline characteristics
In total, 400 patients were included (75% male, mean age 53±14 years); 84 (21%) patients from the Erasmus MC University Medical Center, 224 (56%) patients from Johns Hopkins Hospital and 92 (23%) patients from the Medical University of South Carolina. The Heartmate II device was most frequently implanted: 330 (82%), followed by the HeartWare device 48 (12%), and 22 (6%) patients received a HeartMate 3 device. The baseline characteristics of the 4 groups are presented in Table 1 . Stratified according to preoperative CKD stages, 186 (46.5%) patients had CKD stages 1-2, 93 (23.3%) patients CKD stage 3a, 82 (20.5%) patients CKD stage 3b and 39 (9.8%) patients CKD stage 4 or 5. Patients with a preoperative CKD stage of 1 or 2 were younger (p < 0.001), had more frequently a non-ischemic etiology of their cardiomyopathy (p = 0.03), and lower rates of implantable cardioverter-defibrillator (ICD) or pacemakers (PM) (p = 0.02).
Evolution of eGFR
During the two years following LVAD implantation, 32,629 measurements of eGFR were collected (CKD stage 1 or 2 group: 15,760 (48.3%), CKD stage 3a group: 7,202 (22%), CKD stage 3b group: 6,854 (21%), CKD stage 4 or 5 group: 2,813 (8.6%)). The mean number of serum creatinine measurements per patient was 82 ± 43 . The general evolution of eGFR for all patients is plotted in Figure 1a . Model summary is presented in Supplementary Table 2a . The greatest improvement of kidney function was noted at 90 days post LVAD implantation. In addition, kidney function did not differ from baseline at day 210, and the nadir was noted at day 455 after which kidney function plateaued. need for ECMO and the need for inotropic support had no effect on renal function improvement.
All baseline characteristics differences are noted in Table 2 .
Sustained renal function improvement was observed in 53 (13.2%) patients. Differences in patients with sustained renal function improvement were younger age (47±14 vs 53±13, p=0.001), higher eGFR (65±27 vs 55±24, p=0.02) and less preoperative diabetes (22.6% vs 41.2%, p=0.01).
Thereafter, a subset of the cohort was analyzed with pre-operative (max. 30 days prior to implantation) right heart catheterization (RHC) measurements (n=300) (Table 3a and 3b ). No significant difference in pre-operative RHC measurements between the pre-operative CKD stages was observed. Comparing patients who experienced early renal function improvement to those that did not experience improvement resulted in the following differences: patients who experienced early renal function improvement had lower pre-operative cardiac index, higher mean right arterial pressures, higher right ventricular diastolic pressures higher pulmonary artery diastolic pressures and higher pulmonary capillary wedge pressures. Figure 2 . Furthermore, patients with higher CKD stages required more frequently RRT following LVAD implantation, 12% in the CKD stage 1 & 2, 22%, 22%, and 39% in the CKD stage 3a, stage 3b, and stage 4 & 5 groups (Log-Rank: p<0.001), respectively. Figure 3 compares the 2-year survival rates for patients who did (69,5%) and did not (56,2%) experience early renal function improvement (Log-rank: p=0.013) respectively. Finally, patients with sustained renal function improvement were identified (n=53). Patients with sustained renal function improvement were younger of age (p=0.01), had lower rates of diabetes mellitus (p=0.01), had higher baseline eGFR (p=0.01) and higher mean diastolic pulmonary pressures (p=0.02).
Clinical course
Discussion
The current study evaluated the impact of prolonged LVAD therapy on kidney function. Our principal findings are as follows: (1) The next step in personalized medicine is considering and examining all available data. The appropriate methodology to accurately depict changes takes all individual measurements into consideration. This allows for the use of mixed modelling analyses, depicting more accurate evolutions. This novel approach adjusts both the correlation between patients, and the correlation between measurements of the same patient. Moreover, it adjusts, to a certain degree, for missing data and mortality. This methodology yields the most accurate depiction of renal function evolution following LVAD implantation.
The different phases of renal function
We confirm that the evolution of renal function can be divided into 3 phases. The first phase is characterized by a marked improvement in renal function, which is proportionally greater in patients with higher CKD stages. This phase transpires in the first 70 days following LVAD implantation. Improvement of renal function is most likely driven by improved cardiac output and relief of venous congestion. In HF patients, venous congestion is one of the major factor that drives worsening renal function.(11) Indeed our results show that patients with higher preoperative right atrial pressures, which is closely linked to central venous pressure, were more likely to show early renal function improvement.
The second phase marks the renal recovery phase. This phase initiates following the renal improvement phase and concludes at approximately 150-day of follow-up. This phase represent an opportunity to maintain the regained function from the first phase for as long as possible, perhaps by adjusting the LVAD parameters to provide optimal output, closely monitoring the fluid status and by monitoring/optimizing right ventricle (RV) function.
Lastly, the deterioration phase sets in. This phase is noticed in all baseline CKD stages, suggesting a multifactorial determinant, and could be inherent to contemporary LVAD therapy.
Being the most poorly understood phase, various hypotheses have been proposed. 
Clinical perspectives
The trend of eGFR after LVAD implantation displays an initial improvement of overall mean eGFR. However, subsequent to this improvement, a regression in overall mean eGFR to the baseline is noticed in all patient groups, regardless of eGFR function prior to LVAD implantation. Nonetheless, early renal function improvement is associated with better survival rates following LVAD implantation. Therefore, sole severe renal dysfunction (eGFR <45), should not exclude candidacy for LVAD implantation. Selection criteria should include age, the primary presentation, the setting of LVAD implantation (emergent or elective), the baseline renal function and concomitant hemodynamic profile (renal venous congestion and/or forward failure).
Those with the most severe hemodynamic derangements are most likely to benefit. Additional research is warranted to identify which factors predict, and what the underlying mechanisms are for sustained renal function improvement post LVAD implantation.
Strengths & limitations
There are a number of limitations that should be taken into consideration when interpreting our findings. First, due to the retrospective study design, causality cannot be established. Second, the 
Conclusion
Renal function following LVAD implantation shows a triphasic pattern characterized by significant early improvement, a period of steady state function and subsequent deterioration to baseline. Patients with early renal function improvement were younger, had worse pre-operative condition and CKD stages, but with better survival rates at long-term FU.
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